EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent

N Mottet, RCN van den Bergh, E Briers… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …

Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—updated diagnostic utility, sensitivity, specificity, and …

M Perera, N Papa, M Roberts, M Williams, C Udovicich… - European urology, 2020 - Elsevier
Context Accurate staging of high-risk localised, advanced, and metastatic prostate cancer is
becoming increasingly more important in guiding local and systemic treatment. Gallium-68 …

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective …

MS Hofman, N Lawrentschuk, RJ Francis, C Tang… - The Lancet, 2020 - thelancet.com
Background Conventional imaging using CT and bone scan has insufficient sensitivity when
staging men with high-risk localised prostate cancer. We aimed to investigate whether novel …

Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non …

A Kneebone, C Fraser-Browne, GM Duchesne… - The Lancet …, 2020 - thelancet.com
Background Adjuvant radiotherapy has been shown to halve the risk of biochemical
progression for patients with high-risk disease after radical prostatectomy. Early salvage …

[HTML][HTML] Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of …

S Gillessen, A Bossi, ID Davis, J de Bono, K Fizazi… - European urology, 2023 - Elsevier
Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …

Medical imaging and nuclear medicine: a Lancet Oncology Commission

H Hricak, M Abdel-Wahab, R Atun, MM Lette… - The Lancet …, 2021 - thelancet.com
The diagnosis and treatment of patients with cancer requires access to imaging to ensure
accurate management decisions and optimal outcomes. Our global assessment of imaging …

Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 …

M Roach, J Moughan, CAF Lawton, AP Dicker… - The lancet …, 2018 - thelancet.com
Summary Background The NRG/RTOG 9413 study showed that whole pelvic radiotherapy
(WPRT) plus neoadjuvant hormonal therapy (NHT) improved progression-free survival in …

Optimum imaging strategies for advanced prostate cancer: ASCO guideline

EJ Trabulsi, RB Rumble, H Jadvar, T Hope… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Provide evidence-and expert-based recommendations for optimal use of
imaging in advanced prostate cancer. Due to increases in research and utilization of novel …

Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer …

L Emmett, C Yin, M Crumbaker, G Hruby… - Journal of Nuclear …, 2019 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) may be targeted for both diagnostic and
therapeutic purposes in the management of prostate cancer (PCa). In preclinical models …

PSMA PET in imaging prostate cancer

I Tsechelidis, A Vrachimis - Frontiers in oncology, 2022 - frontiersin.org
After prostate malignancy diagnosis, precise determination of disease extent are
fundamental steps for tailored made therapy. The earlier the diagnosis of the burden of the …